CCCC vs COP · rev $35.6M vs P/E 19, rev $58.94B
C4 Therapeutics Inc (CCCC) versus ConocoPhillips (COP) — a side-by-side from cached financials, not a winner call.
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
CCCC currently screens at market cap $425.7M. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Not investment advice. Open the CCCC and COP stock pages for the full models.
Not investment advice.